Skip to main content
News Wilhelm 07.2022
© AG Wilhelm / UKB

News categories: Publication

Covid-19: Immune response hampered by low availability of ketone bodies

Supply of T-cells with adequate energy carriers deficient in patients suffering from Covid-19

In Covid-19 patients, the metabolism produces energy-rich ketone bodies in insufficient amounts. However, these energy carriers are needed by both helper and killer T-cells in order to fight the virus effectively. Perhaps this finding explains why some people become much more seriously ill than others. A study led by ImmunoSensation2 member Prof. Christoph Wilhelm at least points in this direction. The results have now been published in the journal Nature. They also give hope for new therapeutic approaches.

Infections often are accompanied by a loss in appetite. The consequence is a reduced supply with carbohydrates, which induces a metabolic switch towards fat burning. In this, ketone bodies generated from Acetyl-CoA, provide a high energy source, helping our bodies cope better with pathogens.

At least that is what the results of the current study suggest. "We found that patients with viral flu produce ketone bodies in large quantities," explains Prof. Dr. Christoph Wilhelm from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn. "In contrast, we saw little increase in Covid-19 patients, at least in those with a moderate or severe course."

It was furthermore noticeable that those infected with the coronavirus had lower levels of cytokines in their blood. This was especially true for interferon-gamma, secreted by helper T cells in order to recruit macrophages and further immune cells to the site of infection. For this, however, the helper T cells apparently require an adequate supply of ketone bodies. If this is missing, they produce less interferon-gamma. Moreover, the helper cells then die earlier.

Ketone bodies make immune system more powerful

The researchers also saw similar effects in another important group of immune cells, the killer T cells. "They too require ketone bodies to function well and effectively eliminate the virus," says Dr. Christian Bode, lecturer at the Department of Anesthesiology and Surgical Intensive Care Medicine at the University Hospital Bonn. Apparently, the ketone bodies cause a certain metabolic pathway to be activated in the immune cells. This not only ensures improved energy production, but also provides molecules needed for interferon production.

"Without an adequate supply of ketone bodies, on the other hand, the killer T cells and helper T cells show signs of exhaustion," Bode explains. "In this depleted state, they can no longer perform their function adequately." However, the researchers were able to revive the immune cells by placing sick mice on a ketogenic, or low-carbohydrate, diet or by administering ketone bodies directly. The animals were then better able to eliminate the virus. They also developed significantly less lung damage.

Hope for new treatment options

The results therefore also give hope for new treatment options. "It may be possible to increase the clout of the body's defenses by making specific dietary changes," Wilhelm says. "Further studies must now show whether this really works." The researchers expressly advise against self-experimentation with dietary supplements or diets, which could do more harm than good.

The new findings could also be relevant in other infections. In the medium term, they may even contribute to new strategies to help the body fight tumors.


Participating institutions and funding

In addition to the University Hospital and the University of Bonn, the TU Braunschweig and the University Hospitals of Hannover, Zurich, Nijmegen and Essen were involved in the study. The study was funded by the German Research Foundation (DFG), the German Federal Ministry of Education and Research (BMBF), the European Research Council (ERC), and the Netherlands Organization for Scientific Research (NWO).


Publication

Fotios Karagiannis, Konrad Peukert, Laura Surace, Marcel Michla, Fabian Nikolka,
Mario Fox, Patricia Weiss, Caroline Feuerborn, Paul Maier, Susanne Schulz, Burcu Al, Benjamin Seeliger, Tobias Welte, Sascha David, Inge Grondman, Aline H de Nooijer, Peter Pickkers, Jan Lukas Kleiner, Marc Moritz Berger, Thorsten Brenner, Christian, Putensen, Bonn COVIMMUNE Consortium, Hiroki Kato, Natalio Garbi, Mihai G. Netea,Karsten Hiller, Katarzyna Placek, Christian Bode & Christoph Wilhelm; Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19; Nature; https://www.nature.com/articles/s41586-022-05128-8


Contact

Prof. Dr. Christoph Wilhelm

Institute for Clinical Chemistry and Clinical Pharmacology

University Hospital Bonn

Tel.: +49 (0)228/287-51721

E-Mail: cwilhelm(at)uni-bonn.de

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview